Compare CGBD & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGBD | EVO |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | Germany |
| Employees | 2500 | 4553 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.2M | 934.1M |
| IPO Year | N/A | N/A |
| Metric | CGBD | EVO |
|---|---|---|
| Price | $11.55 | $3.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $12.92 | $7.00 |
| AVG Volume (30 Days) | ★ 858.7K | 107.1K |
| Earning Date | 05-11-2026 | 04-08-2026 |
| Dividend Yield | ★ 14.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.74 | $1.37 |
| Revenue Next Year | $1.80 | $10.05 |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.64 | $2.31 |
| 52 Week High | $14.90 | $4.80 |
| Indicator | CGBD | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 51.88 |
| Support Level | $10.68 | $2.87 |
| Resistance Level | $13.06 | $3.78 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 65.49 | 50.00 |
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.